Prevention of acute adenolymphangitis in brugian filariasis: comparison of the efficacy of ivermectin and diethylcarbamazine, each combined with local treatment of the affected limb.

摘要: Acute attacks of adenolymphangitis (ADL) not only force patients with lymphatic filariasis to seek medical attention but also hasten the progression filarial oedema. Patients filariasis-associated ADL are currently treated repeated courses antifilarial drug diethylcarbamazine (DEC), or without antibiotics and anti-inflammatory agents. In this double-blind, placebo-controlled study, efficacy of local treatment affected limb combined doses ivermectin DEC, in preventing the occurrence Brugia malayi filariasis, was examined. Overall, 120 who had each had at least two previous year were each admitted study time of an ongoing episode ADL. The randomly allocated receive 12, monthly treatments of ivermectin (400 μg/kg), DEC (10 mg/kg) placebo, addition local care limbs. There a significant reduction frequency three groups during the 2-year period (P< 0.001 for comparison). Most importantly, there no significant differences between groups, either end phase or at post-treatment (P> 0.15 comparison), suggesting that foot combined with appropriate use antibiotics antifungals is adequate reduce number attacks. The implications these observations planning morbidity control are discussed.